Haemonetics Corporation (HAE)
-NYSE 41.14 
1.25(3.13%) May 17, 4:00PM EDT
| Prev Close: | 39.89 |
|---|
| Open: | 39.93 |
|---|
| Bid: | 37.44 x 200 |
|---|
| Ask: | 44.83 x 100 |
|---|
| 1y Target Est: | 44.60 |
|---|
| Beta: | 0.71 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 39.92 - 41.14 |
|---|
| 52wk Range: | 32.69 - 44.44 |
|---|
| Volume: | 596,412 |
|---|
| Avg Vol (3m): | 296,844 |
|---|
| Market Cap: | 2.11B |
|---|
| P/E (ttm): | 55.59 |
|---|
| EPS (ttm): | 0.74 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Mark W. Oelschlager, Portfolio Manager at Oak Associates, Ltd., Interviews with The Wall Street Transcript: A Health Sciences Fund with a Long-Term FocusWall Street Transcript(Fri, May 17)
- Haemonetics Corporation - Analyst/Investor Dayat Seeking Alpha(Thu, May 16)
- HAE Crosses Above Key Moving Average Levelat TheStreet(Thu, May 16)
- Bargain Hunters Take Note: Insider Cluster-Buying At HAEat Forbes(Wed, May 8)
- Insiders Buy the Holdings of XSLVat Forbes(Mon, May 6)
- HAE Beats on Earnings, Revs in LineZacks(Fri, May 3)
- HAEMONETICS CORP Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and ExhibiEDGAR Online(Fri, May 3)
- Haemonetics Closes Hemerus AcquisitionZacks(Thu, May 2)
- Haemonetics upgraded to Buy from Hold at Craig-Hallumat theflyonthewall.com(Thu, May 2)
- Haemonetics Corp. Becomes Oversold (HAE)at TheStreet(Wed, May 1)
- Haemonetics Completes Hemerus Medical Acquisitionat Motley Fool(Wed, May 1)
- Haemonetics Management Discusses Q4 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- Haemonetics Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, May 1)
- Haemonetics Corporation Earnings Call scheduled for 8:00 am ET todayCCBN(Wed, May 1)
- Q4 2013 Haemonetics Corporation Earnings Release - Before Market OpenCCBN(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | 15.64 |
|---|
| P/S (ttm): | 2.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 2.33 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.47 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 1.37 |
|---|
Business Summary
Haemonetics Corporation develops and manufactures automated blood component collection and surgical blood salvage devices for plasma fractionators, blood collectors, and hospitals.
View More